Alnylam Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: ALNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
232.68+8.15 (+3.63%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Alnylam Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 164.49M | 205.99M | 111.54M | 251.08M | -72.23M | -18.25M | -83.76M | -111.57M | -16.89M | -65.94M | -137.87M | 147.75M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | -175.51% | — | — | — | — |
| Depreciation & Amortization | — | — | 13.51M | 13.80M | 13.94M | 14.40M | 14.17M | 13.98M | 15.00M | 13.52M | 13.48M | 13.33M |
| Stock-Based Compensation | 86.63M | — | 71.63M | 108.21M | 111.68M | 56.71M | 91.64M | 45.80M | 89.29M | 45.35M | 41.99M | 63.94M |
| Change in Working Capital | — | — | -73.15M | -178.74M | 24.16M | -217.05M | -108.30M | 41.02M | -38.35M | -108.46M | 18.28M | 36.69M |
| Operating Cash Flow | — | — | 163.56M | 351.03M | 127.81M | -118.31M | -94.66M | 43.71M | 124.16M | -81.52M | -29.80M | 359.41M |
| Capital Expenditures | — | — | -23.29M | -12.14M | -14.29M | -8.97M | -9.09M | -4.19M | -8.02M | -12.97M | -15.31M | -17.09M |
| Investing Cash Flow | — | — | -37.17M | 501.11M | -141.38M | 113.77M | -52.91M | -30.25M | 33.94M | -67.62M | -240.66M | -10.76M |
| Financing Cash Flow | — | — | 45.32M | -474.27M | 79.68M | 44.08M | 31.00M | 102.75M | 131.50M | 28.91M | 39.23M | 33.14M |
| Net Change in Cash | — | — | 166.00M | 376.94M | 93.61M | 53.60M | -133.85M | 131.31M | 286.47M | -130.16M | -220.33M | 375.23M |
| Free Cash Flow | — | — | 140.26M | 338.89M | 113.52M | -127.28M | -103.76M | 39.52M | 116.14M | -94.49M | -45.10M | 342.32M |
This table shows 12 quarterly periods of Alnylam Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ALNY's reporting calendar. What is a cash flow statement?